Revenue: As of FY2025 Q3, the actual value is USD 7.171 M.EPS: As of FY2025 Q3, the actual value is USD 0.EBIT: As of FY2025 Q3, the actual value is USD 406 K.<h3>Segment Revenue</h3><ul><li>Total Revenue: For the three months ended September 30, 2025, revenue increased 2.5% to $7.2 million compared to $7.0 million in the prior year period. For the nine months ended September 30, 2025, revenue increased 5.6% to $20.4 million compared to $19.3 million for the first nine months of 2024.</li><li>Direct Patient Care Services: Revenue increased 9.4% to $4.0 million for Q3 2025, representing 56% of total sales, compared to 53% in the prior year period. For the first nine months of 2025, revenue increased 36.5% to $10.7 million compared to $7.8 million in the prior year.</li><li>Medical Equipment Leasing: Revenue decreased 5.3% to $3.1 million for Q3 2025 compared to $3.3 million in the prior year period. For the first nine months of 2025, revenue was $9.7 million compared to $11.5 million in the prior year.</li></ul><h3>Operational Metrics</h3><ul><li>Gross Margin: Improved to 22.1% in Q3 2025, increasing 15.8% to $1.6 million from $1.4 million in Q3 2024. For the first nine months of 2025, gross margins were 20.4% or $4.2 million, compared to $6.0 million for the first nine months of 2024.</li><li>Net Loss: Decreased 91.8% for Q3 2025 to a loss of $17,000 compared to a net loss of $207,000 in Q3 2024. For the first nine months of 2025, net loss was $0.9 million compared to net income of $3.5 million in the prior year.</li><li>Adjusted EBITDA: Increased 42.3% to $1.94 million for Q3 2025 compared to $1.37 million in Q3 2024. For the first nine months of 2025, adjusted EBITDA was $4.6 million compared to $5.1 million in the prior year.</li></ul><h3>Cash Flow</h3><ul><li>Cash, Cash Equivalents, and Restricted Cash: Totaled $5.3 million at September 30, 2025, compared to $11.3 million at December 31, 2024, driven by $7.5 million in capital expenditures during the nine-month period.</li></ul><h3>Outlook / Guidance</h3><ul><li>The company expects further growth in revenue from the new Esprit being installed in the new Gamma Knife center in Guadalajara, Mexico, expected to start in the second quarter of 2026. The company is also focused on expanding its footprint in Rhode Island with new radiation therapy treatment centers, which are expected to contribute to long-term growth and profitability.</li></ul>

American Shared Hosp | 8-K: FY2025 Q3 Revenue: USD 7.171 M